Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT06459024

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Sex: All

Ages: 6 Years – N/A

Healthy volunteers: No

Enrollment: 4000

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Location: University Hospital Aachen Aachen

Summary

This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites

Eligibility Criteria

Inclusion Criteria: * Patients with AML diagnosis according to WHO2022 or ICC2022 * Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria * Participant or his/her legal representative is willing and able to give informed consent for participation in the study Exclusion Criteria: * Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06459024). StuddyBuddy aggregates publicly available trial information.